Navigation Links
QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
Date:5/4/2010

ents (morphine 12 mg and oxycodone 8 mg) was the difference in pain intensity scores from baseline for each patient over the 48-hour treatment period (SPID48).  

Secondary endpoints included: (1) efficacy relating to the amount of supplemental analgesic (ibuprofen) used throughout the treatment period; (2) difference in pain intensity scores from baseline for each patient over the first 24-hour treatment period (SPID24); and (3) safety as measured by incidence and intensity of opioid-related adverse effects.

In terms of supplemental analgesia, patients in the morphine and oxycodone control groups were 2-3 times more likely to use ibuprofen supplemental dosing than those receiving MoxDuo IR (p<0.05 to p<0.01).  Control groups were also more likely to use ibuprofen in greater amounts and earlier in the treatment period than patients receiving MoxDuo IR (p<0.01 to p<0.001).  Even with the extra use of rescue medication in the control groups, at both 24 and 48 hours, the amount of pain reduction from baseline was significantly less compared to patients receiving MoxDuo IR  (p<0.05 to p<0.001).  

The enhanced tolerability of MoxDuo IR seen in earlier studies was further validated in this pivotal Phase 3 combination rule trial.  Whilst patients in the MoxDuo IR (12/8mg) arm received twice the morphine equivalent dose of patients in the other two comparator arms (morphine 12 mg or oxycodone 8mg), the incidence and intensity of moderate to severe side effects remains similar whilst efficacy was higher with MoxDuo IR. This tolerability is further evidenced by the 93% to 95% patient completion rate in the study treatment groups.

"By delivering twice the opioid dose, one would expect a substantial increase in both the incidence and intensity of a broad range of side effects, but that is not the case w
'/>"/>

SOURCE QRxPharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Limited and China Aoxing Pharmaceutical Company Announce Strategic Alliance for Development of MoxDuo(R)IV
2. QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
3. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
4. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
5. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
6. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
7. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
8. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
9. BetterInvesting Magazine Releases Julys Stock to Study and Undervalued Stock Choices for Investors Informational and Educational Use
10. QRS Diagnostic Releases 64-bit and Windows(R) 7 Compatible Software
11. BioVigil Releases Second-Generation Hand Hygiene Monitoring System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:7/12/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE ... of LTE networks continues to grow due to the ... have increased mobile data traffic, which is a major ... Communications Test and Measurement equipment comply with industry standards, ... Test and Measurement Market is estimated to grown from ...
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... Using and carrying around a catheter bag can ... Va., decided that there needed to be an inconspicuous ... of our design," he said. , They then created ... an inconspicuous way to use and carry a catheter’s ... comfort and peace of mind. Producible in design variations, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a ... a subsidiary of Johnson & Johnson, on behalf of an ... receiving a metal-on-metal DePuy Pinnacle hip replacement and had to ... hip implant. The DePuy hip lawsuit was filed July 7, ... (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip lawsuit litigation ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5
... Reporter , TUESDAY, Dec. 13 (HealthDay News) -- Recreational use ... long-term changes in brain chemistry, a small, new study reveals. ... so-called "rave" drug can induce a drop in serotonin levels ... team noted, is critical to the regulation of mood, appetite, ...
... SCOTTSDALE, Ariz. Researchers at Mayo Clinic in Arizona ... have developed a vaccine that dramatically reduces tumors in ... breast and pancreatic cancer cases including those that ... described this week in the early edition of the ...
... suffering from mood and anxiety disorders such as ... more likely to abuse opioids, according to a ... Bloomberg School of Public Health. They found that mood ... opioid use. The results are featured in a recent ...
... Medical Center researchers have discovered how cholesterol-lowering drugs called ... The study was published online by the journal ... findings support a large clinical study that recently showed ... reduced their cholesterol levels but also reduced the amount ...
... Dec. 13 (HealthDay News) -- A short walk can cut ... at work, a new study suggests. U.K. researchers created ... chocolate-eaters but had gone two days without eating chocolate. They ... brisk 15-minute walk on a treadmill and then were given ...
... 13, 2011 UC Irvine researchers have uncovered an ... kidney disease, which is increasingly common due to the ... Vaziri, professor emeritus of medicine and physiology & biophysics, ... adhesive proteins, called the tight junction, that normally seal ...
Cached Medicine News:Health News:'Ecstasy' May Cause Long-Term Changes in Brain Chemistry 2Health News:'Ecstasy' May Cause Long-Term Changes in Brain Chemistry 3Health News:Scientists develop vaccine that successfully attacks breast cancer in mice 2Health News:Scientists develop vaccine that successfully attacks breast cancer in mice 3Health News:Opioid abuse linked to mood and anxiety disorders 2Health News:Opioid abuse linked to mood and anxiety disorders 3Health News:Cholesterol-lowering medication accelerates depletion of plaque in arteries 2Health News:Want to Cut Chocolate Cravings? Take a Walk 2Health News:Major cause of chronic kidney disease-related inflammation is identified 2
For implantation in proximal interphalangeal joints of the lateral toes to correct deformity associated with degenerative or rheumatoid arthritis....
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... a new standard in the field of hammertoe ... Made of medical grade silicone, these durable and ... high level of flexibility while maintaining correct toe ... in varying stiffnesses. Lengths are determined by the ...
... Kinetik Great Toe Implant (KGTI) system offers ... of the first MPJ. The implant system ... of motion. , ,The KGTI is the ... metatarsophalangeal joint (MPJ) on the market today. ...
Medicine Products: